Entera Bio (ENTX) Net Cash Flow Growth (1y) (2022 - 2026)
Entera Bio (ENTX) Net Cash Flow Growth (1y) (2022 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
788,338.31 Bn |
788,338.28 Bn |
- |
- |
| 2 |
Belite Bio |
56,560.00 Bn |
56,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,329.30 Bn |
17,329.30 Bn |
- |
198.34% |
| 4 |
Legend Biotech |
3,341.00 Bn |
3,340.71 Bn |
242.10 Mn |
467.41% |
| 5 |
Akari Therapeutics |
1,727.91 Bn |
1,727.91 Bn |
- |
-14,223.53% |
| 6 |
Evaxion A |
1,536.68 Bn |
1,536.67 Bn |
- |
- |
| 7 |
Psyence Biomedical |
238.34 Bn |
238.33 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
113.42 Bn |
106.17 Bn |
2.59 Bn |
453.08% |
| 9 |
Abivax |
95.45 Bn |
95.45 Bn |
- |
- |
| 10 |
Entera Bio |
57.79 Mn |
53.65 Mn |
- |
-124.82% |
| Date | Value |
|---|
| Mar 31, 2026 |
-124.82% |
| Dec 31, 2025 |
-196.51% |
| Sep 30, 2025 |
-7.19% |
| Jun 30, 2025 |
-1,337.82% |
| Mar 31, 2025 |
750.93% |
| Dec 31, 2024 |
-48.75% |
| Sep 30, 2024 |
-40.39% |
| Jun 30, 2024 |
92.35% |
| Mar 31, 2024 |
-13.09% |
| Dec 31, 2023 |
269.27% |
| Sep 30, 2023 |
47.88% |
| Jun 30, 2023 |
45.11% |
| Mar 31, 2023 |
66.36% |
| Dec 31, 2022 |
19.47% |
| Sep 30, 2022 |
-723.88% |
| Jun 30, 2022 |
-126.87% |
| Mar 31, 2022 |
-161.83% |
